Literature DB >> 29518460

Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review.

Nolan J Maloney1, Lisa D Hisaw2, Scott Worswick3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29518460     DOI: 10.1016/j.jaad.2018.02.063

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  1 in total

1.  Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination.

Authors:  Ya-Ting Liu; Shang-Shang Wang
Journal:  Skin Health Dis       Date:  2022-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.